To compare procedural and long-term costs associated with the use of Balloon-Expandable Covered Stents (BECS) in the management of Aortoiliac Occlusive Disease (AIOD).
Materials and Methods:
A cost-consequence model was developed to simulate the intra- and post-operative management of patients with AIOD from the perspective of private health-payers. The study assessed the costs of the LifeStream (BD, Franklin Lakes, New Jersey), iCAST/Advanta V12 (Getinge, Goteborg, Sweden), BeGraft Peripheral (Bentley, Hechingen, Germany), and Viabahn Balloon Expandable (VBX) (W.L. Gore, Flagstaff, Arizona) BECS devices. Device costs were identified from the Australian Prosthesis List, whereas clinical outcomes of BECS were estimated from a systematic review of the literature. Costs were calculated over 24 and 36 month time horizons and reported in US dollars.
Results:
Long-term, per-patient cost of each device at 24 and 36 months was $6255/$6776 for the LifeStream; $6631/$6870 for the iCAST/Advanta V12; $4807 (data available to 24 months) for the BeGraft Peripheral; and $4839/$5078 for the Viabahn VBX, respectively. Most of the cost difference was attributed to the number of stents required per treated limb and frequency of clinically-driven target lesion revascularization events.
Conclusions:
Best-available clinical evidence and economic modeling demonstrates that the BeGraft Peripheral and Viabahn VBX were of similar cost and the least costly options at 24 months, whereas at 36 months, the lowest cost BECS option for the treatment of AIOD was the Viabahn VBX.
Clinical Impact
This analysis supports economically informed decision-making for health-payers managing systems that care for patients with AIOD. Stent length and avoiding reintervention were identified as key areas of cost-saving for future BECS development.
FowkesFGRudanDRudanI, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329–1140. doi:10.1016/S0140-6736(13)61249-0.
3.
KumarK.Defining the role of covered stents in aorto-iliac interventions. Interventional Cardiology. 2013;5(1):45–52.
4.
MahoneyEMWangKCohenDJ, et al. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008;1(1):38–45. doi:10.1161/CIRCOUTCOMES.108.775247.
5.
RossiMIezziR.Cardiovascular and Interventional Radiological Society of Europe guidelines on endovascular treatment in aortoiliac arterial disease. Cardiovasc Intervent Radiol. 2014;37(1):13–25. doi:10.1007/s00270-013-0741-9.
6.
NorgrenLHiattWRDormandyJA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–67. doi:10.1016/j.jvs.2006.12.037.
7.
ConteMSBradburyAWKolhP, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019;58(1S):S1–S109. doi:10.1016/j.ejvs.2019.05.006.
8.
MwipatayiBPThomasSWongJ, et al. A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg. 2011;54(6):1561–1570. doi:10.1016/j.jvs.2011.06.097.
9.
MwipatayiBPSharmaSDaneshmandA, et al. Durability of the balloon-expandable covered versus bare-metal stents in the Covered versus Balloon Expandable Stent Trial (COBEST) for the treatment of aortoiliac occlusive disease. J Vasc Surg. 2016;64(1):83–94. doi:10.1016/j.jvs.2016.02.064.
10.
ConteMSPomposelliFB.Society for Vascular Surgery Practice guidelines for atherosclerotic occlusive disease of the lower extremities management of asymptomatic disease and claudication. Introduction. J Vasc Surg. 2015;61(suppl 3):1S. doi:10.1016/j.jvs.2014.12.006.
11.
CaroJJBriggsAHSiebertU, et al. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–1. Value Health. 2012;15(6):796–803. doi:10.1016/j.jval.2012.06.012.
12.
LairdJRZellerTHoldenA, et al. Balloon-expandable vascular covered stent in the treatment of iliac artery occlusive disease: 9-month results from the BOLSTER multicenter study. J Vasc Interv Radiol. 2019;30(6):836–844. doi:10.1016/j.jvir.2018.12.031.
BekkenJAVroegindeweijDVosJA, et al. Editor’s choice—Two year results of the randomised DISCOVER trial comparing covered versus bare metal stents in the common iliac artery. Eur J Vasc Endovasc Surg. 2023;65(3):359–368. doi:10.1016/j.ejvs.2022.11.008.
15.
LairdJRLojaMZellerT, et al. ICAST balloon-expandable covered stent for iliac artery lesions: 3-year results from the iCARUS multicenter study. J Vasc Interv Radiol. 2019;30(6):822–829. doi:10.1016/j.jvir.2018.12.707.
BismuthJGrayBHHoldenA, et al. Pivotal study of a next-generation balloon-expandable stent-graft for treatment of iliac occlusive disease. J Endovasc Ther. 2017;24(5):629–637. doi:10.1177/1526602817720463.
19.
PannetonJMBismuthJGrayBH, et al. Three-year follow-up of patients with iliac occlusive disease treated with the Viabahn balloon-expandable endoprosthesis. J Endovasc Ther. 2020;27(5):728–736. doi:10.1177/1526602820920569.
20.
SixtSKrankenbergHMöhrleC, et al. Endovascular treatment for extensive aortoiliac artery reconstruction: a single-center experience based on 1712 interventions. J Endovasc Ther. 2013;20(1):64–73. doi:10.1583/12-4014.1.
TangLParavastuSCVThomasSD, et al. Cost analysis of initial treatment with endovascular revascularization, open surgery, or primary major amputation in patients with peripheral artery disease. J Endovasc Ther. 2018;25(4):504–511. doi:10.1177/1526602818774786.
23.
National Heart Foundation of Australia. Economic cost of acute coronary syndrome in Australia: the cost to individuals and their families. resources.heartfoundation.org.au/images/uploads/publications/Economic_cost_of_ACS_in_Australia__the_cost_to_individulas_and_their_families.pdf. Accessed February 12, 2023.
StewartCCBerhaneselaseEMorshedS.The burden of patients with lower limb amputations in a community safety-net hospital. J Am Acad Orthop Surg. 2022;30(1):e59–e66. doi:10.5435/JAAOS-D-21-00293.
27.
MustaphaJAKatzenBTNevilleRF, et al. Determinants of long-term outcomes and costs in the management of critical limb ischemia: a population-based cohort study. J Am Heart Assoc. 2018;7(16):e009724. doi:10.1161/JAHA.118.009724.
28.
DaviesMGBismuthJSaadWE, et al. Outcomes of reintervention for recurrent disease after percutaneous iliac angioplasty and stenting. J Endovasc Ther. 2011;18(2):169–180. doi:10.1583/10-3257.1.
29.
GaxotteVLaurensBHaulonS, et al. Multicenter trial of the Jostent balloon-expandable stent-graft in renal and iliac artery lesions. J Endovasc Ther. 2003;10(2):361–365. doi:10.1177/152660280301000231.
30.
Society for Vascular Surgery Lower Extremity GuidelinesWritingGConteMSPomposelliFB, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015;61(suppl 3):2S–41S. doi:10.1016/j.jvs.2014.12.009.
31.
SridharanNDBoitetASmithK, et al. Cost-effectiveness analysis of drug-coated therapies in the superficial femoral artery. J Vasc Surg. 2018;67(1):343–352. doi:10.1016/j.jvs.2017.06.112.
32.
SalisburyACLiHVilainKR, et al. Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: results from the IN.PACT SFA II trial. JACC Cardiovasc Interv. 2016;9(22):2343–2352. doi:10.1016/j.jcin.2016.08.036.
33.
KearnsBCThomasSM.Cost-effectiveness of superficial femoral artery endovascular interventions in the UK and Germany: a modelling study. BMJ Open. 2017;7(1):e013460. doi:10.1136/bmjopen-2016-013460.
34.
GrayWAGriffithsRIElroyPWM, et al. Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention. J Med Econ. 2022;25(1):880–887. doi:10.1080/13696998.2022.2088965.
35.
DjerfHSvenssonMNordanstigJ, et al. Editor’s choice—Cost effectiveness of primary stenting in the superficial femoral artery for intermittent claudication: two year results of a randomised multicentre trial. Eur J Vasc Endovasc Surg. 2021;62(4):576–582. doi:10.1016/j.ejvs.2021.07.009.
36.
PietzschJBGeislerBPIkenoF.Cost-effectiveness of orbital atherectomy compared to rotational atherectomy in treating patients with severely calcified coronary artery lesions in Japan. Cardiovasc Interv Ther. 2018;33(4):328–336. doi:10.1007/s12928-017-0488-3.
37.
McCreanorVNowbarARajkumarC, et al. Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial. BMJ Open. 2021;11(2):e044054. doi:10.1136/bmjopen-2020-044054.
38.
FearonWFNishiTDe BruyneB, et al. Clinical outcomes and cost-effectiveness of fractional flow reserve-guided percutaneous coronary intervention in patients with stable coronary artery disease: three-year follow-up of the FAME 2 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation). Circulation. 2018;137(5):480–487. doi:10.1161/CIRCULATIONAHA.117.031907.
39.
Rocha-NevesJFerreiraASousaJ, et al. Endovascular approach versus aortobifemoral bypass grafting: outcomes in extensive aortoiliac occlusive disease. Vasc Endovascular Surg. 2020;54(2):102–110. doi:10.1177/1538574419888815.
40.
ReynoldsMRApruzzesePGalperBZ, et al. Cost-effectiveness of supervised exercise, stenting, and optimal medical care for claudication: results from the claudication: exercise versus endoluminal revascularization (CLEVER) trial. J Am Heart Assoc. 2014;3(6):e001233. doi:10.1161/JAHA.114.001233.
41.
IndesJEMandawatATuggleCT, et al. Endovascular procedures for aorto-iliac occlusive disease are associated with superior short-term clinical and economic outcomes compared with open surgery in the inpatient population. J Vasc Surg. 2010;52(5):1173–1179. doi:10.1016/j.jvs.2010.05.100.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
